ClinicalTrials.gg
RecruitingNCT07703917Updated Sep 28, 2026

TENS for Postpartum Uterine Pain During Breastfeeding

An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) in Breast Feeding, sponsored by Holy Family Hospital, Nazareth, Israel. Recruiting at 2 sites in Israel. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Holy Family Hospital, Nazareth, Israel · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Breast Feeding with a site in Israel — 4 open to participants now, 4 under way, none of them phase 3. Breast Feeding · Israel.

Planned enrollment
6th of 15
124 · median 60
Started
2026
with 1 other
No phase
11 of 21
2 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Holy Family Hospital, Nazareth, Israel

Among the 21 studies in Breast Feeding with a site in Israel, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 21st registered.

Breast Feeding

1,083 studies on the registry are indexed under Breast Feeding; 218 are open to participants now.

Browse Breast Feeding studies →

Open to participants now

4 of the 21 studies in Breast Feeding with a site in Israel are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Breast Feeding with a site in Israel, or all of them as a file.
02

Study summary

This clinical study is designed to evaluate whether Transcutaneous Electrical Nerve Stimulation (TENS) is an effective, non-drug method to relieve postpartum uterine pain during breastfeeding in multiparous women (women who have given birth multiple times). Breastfeeding in the first 48 hours after delivery often triggers strong, painful uterine contractions due to the natural release of oxytocin. While standard care typically relies on pain-relief medications, this study investigates if TENS, a safe, low-cost device that sends gentle electrical impulses through small skin patches, can significantly reduce this pain and decrease the need for systemic medications. Participants will be randomly assigned to either receive standard postpartum pain medications or use a TENS device during two consecutive breastfeeding sessions. Researchers will measure and compare the peak pain levels between both groups using a standard 0 to 10 pain scale. The aim is examining whether TENS will significantly reduce postpartum uterine pain during breastfeeding and decrease medication use compared with standard care.

Read the detailed description

This randomized, controlled, parallel-group clinical trial will evaluate the efficacy and safety of Transcutaneous Electrical Nerve Stimulation (TENS) as a non-pharmacological intervention for reducing oxytocin-induced postpartum uterine contractions during breastfeeding. The study cohort consists of 124 eligible multiparous women (2 or more previous births) admitted to the Department of Obstetrics and Gynecology at Holy Family Hospital in Nazareth, Israel, within 48 hours following a term, singleton, vaginal delivery. Following the acquisition of written informed consent, participants will be randomized at a 1:1 ratio into either the TENS study group or the standard care control group. The experimental protocol will be integrated into two consecutive breastfeeding sessions. Body positioning will be strictly standardized across both cohorts. TENS Study Group (Intervention): Prior to the second consecutive breastfeeding session, four conductive gel electrodes will be affixed to the participant. Two electrodes will be positioned bilaterally over the lower abdomen, directly overlying the uterus. The remaining two electrodes will be placed in parallel in the S2-S4 dermatomal region to target the spinal nerve pathways receiving nociceptive afferent input from the uterus and cervix. Active stimulation will commence a few minutes prior to breastfeeding and continue for the entire duration of the feed. The TENS device will deliver 80-Hz current and 200 msec pulse for 40 min, using 20-40 milliamps of intensity.

To establish a baseline pain score, the first evaluated breastfeeding session for this group will be conducted without TENS application, followed by active TENS during the second session. Control Group Protocol: Participants assigned to the control group will receive standard postpartum care and will undergo the identical data collection schedule across two consecutive breastfeeding sessions, but without any TENS electrode placement or electrical stimulation.

For both study arms, pharmacological analgesia will remain accessible as needed per existing institutional department protocols, and all instances of medication administration (including specific agent, timing, and dosage) will be precisely documented. Uterine pain scores will be captured across both groups at three identical time points during each of the two consecutive breastfeeding sessions: Maternal discomfort associated directly with the physical application or sensation of the TENS unit will be separately quantified.

03

Conditions studied

  • Breast Feeding

Browse trials for

Keywords

  • BREASTFEEDING
  • TENS
  • POSTPARTUM PAIN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maternal Age above 18
  • Term delivery (37 weeks or more)
  • Vaginal delivery within the past 48 hours.
  • Multiparous women (2 or more previous births)
  • Delivery of a singleton
  • Have the well to breastfeed

Exclusion criteria

Exclusion Criteria:

  • to TENS (pacemaker, epilepsy, active infection, uncontrolled hyper / hypotension.)
  • Chronic analgesia use
  • Severe complications requiring intervention (severe PPH) or intensive care
  • Skin lesions, infections, or scars at proposed electrode sites
  • Neonatal intensive care unit admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    TENS Group

    This arm is receiving the active clinical intervention being evaluated in the study (the TENS device). Pain scores will be assessed during two consecutive breastfeeding sessions. The first with, and the second without TENS.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS)

  • No intervention
    No-TENS Control Group

    Participants assigned to this control group will receive standard postpartum care only, without any TENS application. Pain scores will be assessed during two consecutive breastfeeding sessions within the first 48 hours postpartum to serve as a comparative baseline against the intervention group.

Interventions

  • DeviceTranscutaneous Electrical Nerve Stimulation (TENS)

    Bilateral application of four skin electrodes using conductive gel. Two electrodes will be placed on the lower abdomen over the uterus, and two will be placed in parallel in the S2-S4 sacral region. The digital sensory-motor TENS device will be programmed to generate 80-Hz current and 200 msec pulse for 40 min, using 20-40 mA of intensity. Stimulation begins a few minutes before breastfeeding and continues throughout the 40-minute session.

06

What researchers measure

Primary outcomes

  1. Peak VAS pain score during breastfeeding in the second session

    The maximum VAS score recorded will be compared between groups. Postpartum uterine pain during breastfeeding will be evaluated using a standard Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: During the second breastfeeding session, within the first 48 hours postpartum

Secondary outcomes

  1. Consumption of Pharmacological Analgesics

    Total dosage (mg) of pain relief medications consumed by the participant within the first 48 hours postpartum.

    Time frame: First 48 hours postpartum

  2. Peak VAS pain score during breastfeeding in the second compared with the first sessions.

    The maximum VAS score in the first and second session will be recorded and compared within the same group. Postpartum uterine pain during breastfeeding will be evaluated using a standard Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: During two consecutive breastfeeding sessions within the first 48 hours postpartum

  3. Duration of breastfeeding sessions.

    The time, in minutes, that the woman is able to continue breastfeeding.

    Time frame: In the two consecutive breastfeeding sessions within the first 48 hours postpartum

  4. Adverse effects related to TENS use

    Local adverse effects related to TENS in the intervention group.

    Time frame: During the second session, within the first 48 hours postpartum

  5. Maternal discomfort

    The women will also be asked to estimate the discomfort of the TENS use using a 5-point verbal scale from no discomfort (0) to worst possible discomfort (5).

    Time frame: First 48 hours postpartum

  6. Formula use

    Use of any infant formula in addition to breastfeeding

    Time frame: First 48 hours postpartum

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • McKay TB, Priyadarsini S, Karamichos D. Mechanisms of Collagen Crosslinking in Diabetes and Keratoconus. Cells. 2019 Oct 11;8(10):1239. doi: 10.3390/cells8101239. PubMed 31614631 ↗
  • Alswied A, Chen LN, West-Mitchell KA. Longitudinal assessment of erythrogram parameters in response to granulocytapheresis frequency: A sex-based analysis. Vox Sang. 2025 Mar;120(3):268-276. doi: 10.1111/vox.13788. Epub 2025 Jan 1. PubMed 39743343 ↗
  • Vera Pingitore E, Hebert EM, Sesma F, Nader-Macias ME. Influence of vitamins and osmolites on growth and bacteriocin production by Lactobacillus salivarius CRL 1328 in a chemically defined medium. Can J Microbiol. 2009 Mar;55(3):304-10. doi: 10.1139/w08-092. PubMed 19370073 ↗
  • Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand. 2007;86(2):185-90. doi: 10.1080/00016340601110770. PubMed 17364281 ↗
  • Radhakrishnan R, Moore SA, Sluka KA. Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain. 2003 Aug;104(3):567-577. doi: 10.1016/S0304-3959(03)00114-3. PubMed 12927629 ↗
  • Silbert BI, Lam SJ, Henderson RD, Lake FR. Students as teachers. Med J Aust. 2013 Dec 16;199(11):757. doi: 10.5694/mja13.11353. No abstract available. PubMed 24329649 ↗

Individual participant data

Plan to share: Yes — Individual patient data (IPD) that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication (starting 6 months after publication).

Access criteria: De-identified IPD will be available to academic or clinical researchers for meta-analyses, and research addressing questions related to the study topic. Requests must include a research protocol, statistical analysis plan, ethics approval, and details of the research team. Requests will be reviewed by the principal investigator. Data will be provided after approval and completion of a data-sharing agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.

Of 504 non-industry interventional studies with no phase under Breast Feeding, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 10 months is below that.

Counting every sponsor, half of 512 studies reached it within 12 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 15, 2026
StartActual
Aug 15, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, description and arm descriptions
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07703917
Lead sponsor
Holy Family Hospital, Nazareth, Israel
Responsible party
Raed Salim, MD (PROFESSOR, Holy Family Hospital, Nazareth, Israel) — Principal investigator
First posted
Jul 15, 2026
Start date
Aug 15, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Marwa Bayatra, MD
Contact
bayatra7@gmail.com
97246508900
RAED SALIM, PROF
Contact
r.salim@hfhosp.org
97246508900
Raed Salim, M.D.
study chair · Holy Family Hospital, Nazareth, Israel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion